glp 1 latest news The GLP-1 revolution: What UAB researchers are discovering about how these drugs work Q&A: GLP-1 medications - The

The net benefit of GLP-1 receptor agonists in adults with overweight or obesity who do not have diabetes depends on their weight loss target and willingness to accept harms, according to researchers.Although GLP-1 receptor agonists have demonstrated effectiveness in reducing weight loss and risks for other chronic diseases, questions remain over whether the benefits outweigh the harms of the

This guide is not about whether GLP-1 medications work

In most major obesity trials, GLP-1 therapy was: Escalated to high or maximum tolerated doses Stopped abruptly, not down-titrated Followed by little or no continuation of structured lifestyle support In the STEP-1 extension trial (semaglutide 2.4 mg), participants who discontinued therapy regained approximately two-thirds of their prior weight loss over the following year

However, there may be unappreciated benefits of this combination of therapies

The high prevalence of comorbidities such as diabetes, visceral obesity, and aging, which contribute to systemic inflammation, plays a pivotal role in the pathogenesis and progression of HFpEF